Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Estriol may ease menopause-related cognitive decline
Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.
Clinical Report: Estriol may ease menopause-related cognitive decline
Overview
A case series involving 20 menopausal women indicated that estriol-based hormone treatment may improve cognitive symptoms over 12 months. Statistically significant improvements were observed across multiple cognitive domains, although the study lacked a control group and randomization.
Background
Cognitive decline during menopause is a significant concern for many women, impacting quality of life and daily functioning. Hormonal changes associated with menopause can lead to various cognitive symptoms, and understanding potential treatments is crucial for managing these effects. This study explores the role of estriol, a form of estrogen, in alleviating cognitive decline in menopausal women.
Data Highlights
Parameter
Results
Participants
20 menopausal women
Mean Age
53.5 years
Estriol Doses
2 mg (n=10), 4 mg (n=7), 8 mg (n=3)
Progesterone Doses
100 mg (n=15), 200 mg (n=2), 0 mg (n=3)
Cognitive Domains Assessed
6 (brain fog, concentration, working memory, processing speed, verbal memory, problem solving)
Improvement
Statistically significant across all domains
Key Findings
20 menopausal women reported cognitive improvements after 12 months of estriol treatment.
Statistically significant enhancements were observed in all assessed cognitive domains.
Subgroup analyses showed improvements across various demographics without significant differences in outcomes.
Preclinical studies in mice indicated estriol may reduce cognitive deficits and glial activation.
Estrogen receptor beta signaling in astrocytes may play a role in cognitive effects of estriol.
The study's limitations include lack of randomization and reliance on self-reported cognitive symptoms.
Clinical Implications
Clinicians should consider the limitations of this study when discussing treatment options with patients.
Conclusion
This preliminary study indicates that estriol-based treatment warrants further investigation for cognitive symptoms associated with menopause.
